Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?

We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.